BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19885925)

  • 21. Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer.
    Newlin HE; Amdur RJ; Riggs CE; Morris CG; Kirwan JM; Mendenhall WM
    Cancer; 2010 Oct; 116(19):4533-40. PubMed ID: 20572028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late chemo-intensification with cisplatin and 5-fluorouracil as an adjunct to radiotherapy: a pragmatic approach for locally advanced head and neck squamous cell carcinoma.
    Chufal KS; Rastogi M; Srivastava M; Pant MC; Bhatt ML
    Oral Oncol; 2006 May; 42(5):517-25. PubMed ID: 16480913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
    Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II clinical trial of parenteral hydroxyurea and hyper-fractionated, accelerated external beam radiation therapy in patients with advanced squamous cell carcinoma of the head and neck: toxicity and efficacy with continuous ribonucleoside reductase inhibition.
    Beitler JJ; Smith RV; Owen RP; Silver CE; Mazumdar M; Wadler S
    Head Neck; 2007 Jan; 29(1):18-25. PubMed ID: 16983691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. concomitant chemoradiotherapy with mitomycin C and cisplatin in advanced unresectable carcinoma of the head and neck: phase I-II clinical study.
    Strojan P; Karner K; Smid L; Soba E; Fajdiga I; Jancar B; Anicin A; Budihna M; Zakotnik B
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):365-72. PubMed ID: 18394816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).
    Rischin D; Peters L; Fisher R; Macann A; Denham J; Poulsen M; Jackson M; Kenny L; Penniment M; Corry J; Lamb D; McClure B
    J Clin Oncol; 2005 Jan; 23(1):79-87. PubMed ID: 15625362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of locally advanced cervical cancer with concurrent radiation and intra-arterial chemotherapy.
    Morris M; Eifel PJ; Burke TW; McNamara MM; Levenback C; Kavanagh JJ; Gershenson DM
    Gynecol Oncol; 1995 Apr; 57(1):72-8. PubMed ID: 7705704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer.
    Beckmann GK; Hoppe F; Pfreundner L; Flentje MP
    Head Neck; 2005 Jan; 27(1):36-43. PubMed ID: 15459918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accelerated hyperfractionated irradiation with concomitant boost for stage II laryngeal cancer and locally advanced head and neck cancer.
    Ishii K; Tashiro M; Hosono M; Fukuda H; Takada Y; Kondo S; Inoue Y; Iguchi H; Kusuki M; Yamane H
    Acta Otolaryngol Suppl; 2004 Oct; (554):62-6. PubMed ID: 15513514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of prognostic variables among patients with locally advanced head and neck cancer treated with late chemo-intensification protocol: impact of nodal density and total tumor volume.
    Chufal KS; Rastogi M; Srivastava M; Pant MC; Bhatt ML; Srivastava K
    Jpn J Clin Oncol; 2006 Sep; 36(9):537-46. PubMed ID: 16905755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concomitant boost radiotherapy with concurrent weekly cisplatin in advanced head and neck cancers: a phase II trial.
    Kumar S; Pandey M; Lal P; Rastogi N; Maria Das KJ; Dimri K
    Radiother Oncol; 2005 May; 75(2):186-92. PubMed ID: 16086908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck.
    Tsukuda M; Ishitoya J; Matsuda H; Horiuchi C; Taguchi T; Takahashi M; Nishimura G; Kawakami M; Watanabe M; Niho T; Kawano T; Ikeda Y; Sakuma Y; Shiono O; Komatsu M
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):729-36. PubMed ID: 20033810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615.
    Robbins KT; Kumar P; Harris J; McCulloch T; Cmelak A; Sofferman R; Levine P; Weisman R; Wilson W; Weymuller E; Fu K
    J Clin Oncol; 2005 Mar; 23(7):1447-54. PubMed ID: 15735120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurotoxicity in a phase I trial of continuous infusion cisplatin with hyperfractionated radiotherapy for locally advanced head and neck cancer.
    Clamon GH; Baatz L; Hoffman HT; Hussey DH; Glascock M; McCulloch TM; Graham SM
    Head Neck; 1996; 18(3):236-41. PubMed ID: 8860764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
    J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of oral S-1 plus Cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
    Kaira K; Sunaga N; Yanagitani N; Kawata T; Utsugi M; Shimizu K; Ebara T; Kawamura H; Nonaka T; Ishikawa H; Sakurai H; Suga T; Hara K; Hisada T; Ishizuka T; Nakano T; Mori M
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):109-14. PubMed ID: 18929446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maximum tolerated dose and early response - results of a phase I trial of paclitaxel and cisplatin with radiation therapy in carcinoma of the cervix.
    Prasad E; Viswanathan PN; Rangad VF; Pavamani S; Ram TS
    Clin Oncol (R Coll Radiol); 2009 Aug; 21(6):488-93. PubMed ID: 19386478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94).
    Ghadjar P; Simcock M; Zimmermann F; Betz M; Bodis S; Bernier J; Studer G; Aebersold DM;
    Radiother Oncol; 2012 Aug; 104(2):213-8. PubMed ID: 22726581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer.
    Allal AS; Zwahlen D; Becker M; Dulguerov P; Mach N
    Cancer J; 2006; 12(1):63-8. PubMed ID: 16613664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of weekly docetaxel and cisplatin arterial infusion for recurrent head and neck cancer.
    Nakamura T; Fuwa N; Takayama K; Inokuchi H; Tomoda T; Takada A; Makita C; Shiomi M; Yokouchi J; Watanabe K
    Head Neck; 2012 Nov; 34(11):1634-9. PubMed ID: 22179897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.